Literature DB >> 23188718

The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms.

Vesna Spasovski1, Natasa Tosic, Gordana Nikcevic, Maja Stojiljkovic, Branka Zukic, Milena Radmilovic, Teodora Karan-Djurasevic, Sanja Srzentic, Milica Colovic, Sonja Pavlovic.   

Abstract

The expression of Janus kinase 2 (JAK2) gene is altered in myeloproliferative neoplasms (MPN) and the regulation of transcription could be a mechanism that modulates JAK2 gene expression. We analyzed the transcriptional potential of single-nucleotide polymorphism (SNP) rs12343867 T > C in JAK2 intron 14, tagging 46/1 haplotype, and its influence on JAK2 gene expression. Functional analysis of JAK2 intron 14 was performed using the pBLCAT5 reporter system in K562 cells. Identification of the proteins binding to the intron 14 regulatory element was accomplished by electrophoretic mobility shift assay (EMSA) and supershift assays. Quantification of the expression of JAK2 gene in a cohort of 51 MPN patients and 12 healthy controls was performed by real-time quantitative polymerase chain reaction (RQ-PCR). Functional analysis revealed that the intronic DNA element harboring SNP rs12343867 T > C acts as a transcriptional repressor in vitro. The repressor activity was significantly attenuated by the presence of nucleotide C. Supershift analysis showed the enrolment of transcriptional factor Meis1 in this process. RQ-PCR experiments showed increased JAK2 expression in patients with the JAK2V617F mutation, with a significant difference between essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) patients. SNP rs12343867 showed no statistically significant influence on the expression of JAK2 gene in MNP patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23188718     DOI: 10.1007/s13353-012-0125-x

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  21 in total

1.  Three-amino acid extension loop homeodomain proteins Meis2 and TGIF differentially regulate transcription.

Authors:  Y Yang; C K Hwang; U M D'Souza; S H Lee; E Junn; M M Mouradian
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

2.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors:  Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

3.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

Review 4.  Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.

Authors:  Isabelle Plo; William Vainchenker
Journal:  Clin Lymphoma Myeloma       Date:  2009

5.  Functional analysis of the role of the TPMT gene promoter VNTR polymorphism in TPMT gene transcription.

Authors:  Branka Zukic; Milena Radmilovic; Maja Stojiljkovic; Natasa Tosic; Farzin Pourfarzad; Lidija Dokmanovic; Dragana Janic; Natasa Colovic; Sjaak Philipsen; George P Patrinos; Sonja Pavlovic
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Authors:  Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

8.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

9.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

Authors:  Francis H Grand; Claire E Hidalgo-Curtis; Thomas Ernst; Katerina Zoi; Christine Zoi; Carolann McGuire; Sebastian Kreil; Amy Jones; Joannah Score; Georgia Metzgeroth; David Oscier; Andrew Hall; Christian Brandts; Hubert Serve; Andreas Reiter; Andrew J Chase; Nicholas C P Cross
Journal:  Blood       Date:  2009-04-22       Impact factor: 22.113

10.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

View more
  6 in total

1.  Sequence variation, differential expression, and divergent evolution in starch-related genes among accessions of Arabidopsis thaliana.

Authors:  Sandra Schwarte; Fanny Wegner; Katja Havenstein; Detlef Groth; Martin Steup; Ralph Tiedemann
Journal:  Plant Mol Biol       Date:  2015-02-08       Impact factor: 4.076

2.  New PAH gene promoter KLF1 and 3'-region C/EBPalpha motifs influence transcription in vitro.

Authors:  Kristel Klaassen; Biljana Stankovic; Nikola Kotur; Maja Djordjevic; Branka Zukic; Gordana Nikcevic; Milena Ugrin; Vesna Spasovski; Sanja Srzentic; Sonja Pavlovic; Maja Stojiljkovic
Journal:  J Appl Genet       Date:  2016-07-22       Impact factor: 3.240

3.  Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.

Authors:  Hiro Takahashi; Kimie Sai; Yoshiro Saito; Nahoko Kaniwa; Yasuhiro Matsumura; Tetsuya Hamaguchi; Yasuhiro Shimada; Atsushi Ohtsu; Takayuki Yoshino; Toshihiko Doi; Haruhiro Okuda; Risa Ichinohe; Anna Takahashi; Ayano Doi; Yoko Odaka; Misuzu Okuyama; Nagahiro Saijo; Jun-ichi Sawada; Hiromi Sakamoto; Teruhiko Yoshida
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

4.  JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.

Authors:  Paolo Catarsi; Vittorio Rosti; Giacomo Morreale; Valentina Poletto; Laura Villani; Roberto Bertorelli; Matteo Pedrazzini; Michele Zorzetto; Giovanni Barosi
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

Review 5.  Single nucleotide polymorphisms and cancer susceptibility.

Authors:  Na Deng; Heng Zhou; Hua Fan; Yuan Yuan
Journal:  Oncotarget       Date:  2017-11-07

Review 6.  The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?

Authors:  Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Francesco Albano
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.